← Home

MEM

Healthcare & BiotechBREAKOUT

$0.008

as of 2026-07-27

Who's been buying — 30 days

net $, conviction-weighted
RetailRetail · context+$362k
NIBInvestment banks+$67k
MMMarket makers+$29k
WAWealth & advisers+$25k
ResResource specialists−$40k

5d return

+0.0%

20d return

+33.3%

60d return

+60.0%

RSI 14

57.1

vs 52w high

+0.0%

vs 52w low

+166.7%

SMA 20

Above

SMA 50

Above

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike. Flow bars stacked per broker group. Flow lags T+3.
Loading chart…
Closest correlates
Pearson r on log returns, window: 42d
  • LINr=0.37, window: 42d
  • CXOr=0.35, window: 42d
  • TLGr=0.34, window: 42d
  • ARUr=0.34, window: 42d
  • RNUr=0.32, window: 42d
Announcements — last 30 days
  • 2026-07-22Proposed issue of securities - MEM
  • 2026-07-22Notice of General Meeting/Proxy Form
  • 2026-07-16PSmre_updateQuarterly Activities/Appendix 4C Cash Flow Report

    MEM posted record Q2 revenue of $150k with significant near-term catalysts (Turkish, Indian, Vietnamese regulatory approvals expected Q3 FY26) and landmark distribution agreements totalling ~$3m contracted value across MENA, Europe, Southeast Asia, and Australia, substantially improving cash runway and burn trajectory. However, revenue remains invoiced late in quarter with cash collection deferred, and commercialisation depends critically on imminent regulatory approvals in multiple jurisdictions.

  • 2026-07-06Memphasys Enters into Consulting Agreement with Director
  • 2026-07-01PSRETAILExclusive Thailand Commercialisation Agreement Secured

    MEM secured an exclusive three-year Thai distribution agreement for Felix sperm-separation technology worth A$430.5K, bringing SE Asia contracted revenue to ~A$1M and FY2026 total contracted Felix sales to A$3M, pending Thai FDA approval within 3–6 months. The agreement leverages IVF Envimed's established relationships with all 110 Thai IVF clinics to drive recurring revenue from single-use cartridges in a high-volume ICSI-dependent market.